Pharma Mar stock
Price history
−11.04% over the period1 year: from €75.65 (November 17, 2025) to €67.30 (November 16, 2026), −11.04%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 16, 2026 | €67.30 |
| October 30, 2026 | €67.50 |
| September 30, 2026 | €73.10 |
| August 31, 2026 | €81.35 |
| July 31, 2026 | €79.05 |
| June 30, 2026 | €75.45 |
| May 29, 2026 | €100.00 |
| April 30, 2026 | €96.00 |
| March 31, 2026 | €87.40 |
| February 27, 2026 | €80.25 |
| January 30, 2026 | €78.95 |
| December 31, 2025 | €74.90 |
| November 28, 2025 | €75.25 |
| November 17, 2025 | €75.65 |
At a glance
The company
Biopharmaceutical company focused on researching, developing and commercializing cancer treatments and gene-silencing therapies
Latest results
Quarter to June 30, 2026 · EPS -€0.06 (estimate €0.18)
TickerLandia's take on Pharma Mar
- Priced as usual relative to earnings: P/E on the latest fiscal year 16 vs a median of 17 over its last 5 fiscal years.
- Pricier than similar companies: trailing 12-month P/E 17 vs 12 (+41%) in a group of 7.
- Strong point: Profitability (73/100 in its group). Weak point: Market momentum (10/100).
- “Most upside for analysts” (Spain): No. 2 of 44.
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−36.03% from the 52-week high
Analysts · 8 analysts
Average target€100.56+49.42% vs. price
Buy 6 · Hold 2 · Sell 0
TickerLandia Fingerprint: Pharma Mar
Compared with similar companies: very weak momentum.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricelow28
How much it costs relative to what it produces.
Metric Value Position in group Price/book 4.92 44 P/E (trailing 12 months) 17.1 17 Forward P/E 13.6 17 EV/EBITDA 18.7 36 Price/sales 4.89 25 Profitabilityhigh73
How much it earns on revenue and capital.
Metric Value Position in group Net margin 28.8% 75 Operating margin 21.3% 55 ROE 31.5% 82 Gross margin 93.3% 84 ROA 8.4% 69 Earnings stabilityhigh72
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 17.4% 59 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 84 Growthaverage48
How fast revenue and earnings are growing.
Metric Value Position in group Revenue growth (year over year) +52.60% 82 Average revenue growth (3 years) +4.08% 13 Financial strengthlow40
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Current ratio 2.36 29 Net debt/EBITDAcounts in reverse: lower means more financial strength 0.40 28 Interest coverage 24.7 64 Debt/equitycounts in reverse: lower means more financial strength 0.30 39 Dividendhigh61
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years 7 years 65 Dividend yield 1.5% 75 Payout ratio 25.4% 42 Market momentumvery weak10
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) −19.82% 8 Relative strength (6 months) −39.05% 5 1-year return −10.93% 18 Distance from 200-day average −17.31% 7 Riskaverage51
How much the price swings.
Metric Value Position in group Beta (1 year) 0.46 24 Volatility (60 days) 25.8% 45 Maximum drawdown (12 months) 38.0% 84
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Pharma Mar is priced as in the past and pricier than similar companies
On the latest fiscal year's earnings (2025), Pharma Mar's P/E today is 15.7, in line with the median of its last 5 fiscal years (17.4; between 9.48 and 53.6 from 2020 to 2025). Pharma Mar's P/E (trailing 12 months): 17.2, +41% against the median of a group of 7 similar companies (12.2).
Compared with 7 similar companies
| Metric | Pharma Mar | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 17.2 | Middle | |
| Forward P/E | 13.7 | Low | |
| Operating margin | 21.3% | Middle | |
| ROE | 31.5% | High | |
| Debt/equity | 0.30 | Middle |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Pharma Mar. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
€49.61M
Latest quarter · Q2 2026
Net income
-€972K
Latest quarter · Q2 2026
Quarterly net margin
-2.0%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- €1.17B
- P/E
- 17.2
- EPS
- €3.93
- Volume
- 4.31K
- Daily trading
- €2.75M
- Dividend yield
- 1.49%
- Last ex-dividend on July 8, 2026
How Pharma Mar is changing
All resultsRevenue fell 3.9% a year on average over the last 5 years
Operating margin rose from 21.4% to 27.4%
Less cash than profit: free cash flow equal to 9% of net income
Returns
Pharma Mar returns with dividends
€1,000 invested in Pharma Mar 5 years ago, on November 16, 2021, would be worth €1,174 today with dividends reinvested: +17.45% in total, +3.27% per year. On price alone it would be €1,097 (+9.68%).
| Period | Pharma Mar | IBEX 35 | €1,000 becomes |
|---|---|---|---|
| 1 month | −0.88% | +4.21% | €991 |
| 6 months | −30.11% | +13.60% | €699 |
| Year to date | −10.15% | +15.67% | €899 |
| 1 year | −9.95% | +23.79% | €901 |
| 3 years | +87.65% | +107.09% | €1,876 |
| 5 years | +17.45% | +121.46% | €1,174 |
| 10 years | +119.07% | +131.75% | €2,191 |
Over the last 6 months it has done better than 2% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. IBEX 35: price only. Calculate your investment
The chart in detail
Pharma Mar: technical analysis
Pharma Mar is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 78.0% below its all-time closing high (€306.00, October 6, 2000).
- Trend
- Downward
- RSI (14 sessions)
- 45
- Between 30 and 70
- vs 200-session average
- −17.20%
Support and resistance
Price areas where Pharma Mar has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance€78.48+16.62%3 touches, last on February 10, 2026
- Resistance€74.31+10.42%4 touches, last on August 6, 2026
- Resistance€72.55+7.80%2 touches, last on December 18, 2025
- Last price€67.30
- No support below: the price is near the lows of the year
Volatility and risk
Over the last year it has moved less than the IBEX 35.
- Beta (1 year) vs IBEX 35
- 0.46
- Volatility (60 sessions, annualised)
- 25.7%
- Largest fall in the last year
- −37.98%
In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Pharma Mar: seasonality
Average monthly price change over 27 years
Over the last 27 years, the strongest month for Pharma Mar has been January: +5.91% on average, positive in 19 years out of 26. The weakest has been June: −4.89% on average, positive in 7 years out of 26. November, the current month, has been positive in 9 years out of 26 (−2.86% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +5.91% | +5.81% | 19 of 26 |
| February | +0.50% | −0.95% | 12 of 26 |
| March | +0.28% | +0.08% | 13 of 26 |
| April | +5.46% | +1.73% | 16 of 26 |
| May | +0.97% | +2.35% | 15 of 26 |
| June | −4.89% | −5.69% | 7 of 26 |
| July | −0.96% | −0.64% | 13 of 26 |
| August | +2.68% | −0.12% | 13 of 26 |
| September | +0.27% | −1.30% | 13 of 26 |
| October | +0.86% | −0.30% | 13 of 27 |
| November | −2.86% | −1.13% | 9 of 26 |
| December | −2.34% | −1.55% | 9 of 26 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Pharma Mar and its competitors
Pharma Mar, S.A. is based in Madrid, Spain, where it was incorporated in 1986. The biopharmaceutical company researches, develops, produces and commercializes bio-active compounds for oncology, selling its treatments in Spain, Germany, Ireland, France, Switzerland, the rest of the European Union, the United States and other markets. Its best-known products include Yondelis, for soft tissue sarcoma and ovarian cancer, Zepzelca, for small cell lung cancer, and Aplidin, for multiple myeloma.
- Headquarters
- Madrid, Spain
- Employees
- 505
- Founded
- 1986
- Chief executive
- Jose Fernandez Sousa-Faro
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Pharma MarPHM | $1.29B | 21.3% | 17.2 | −30.11% |
| IdorsiaIDIA | $1.26B | -68.4% | — | −10.71% |
| Basilea PharmaceuticaBSLN | $1.07B | 24.2% | 18.1 | +31.94% |
| PhilogenPHIL | $920.79M | 79.1% | 4.01 | −7.33% |
| InventivaIVA | $895.83M | -5,980.9% | — | −27.86% |
| Pharming GroupPHARM | $892.54M | 12.8% | 38.0 | +3.70% |
Same industry or related industries, similar size. Compare Pharma Mar with its competitors · Full profile
